← Back to Screener
Opko Health Inc. (OPK)
Price$1.22
Favorite Metrics
Price vs S&P 500 (26W)-26.09%
Price vs S&P 500 (4W)-2.05%
Market Capitalization$926.06M
All Metrics
Book Value / Share (Quarterly)$1.67
P/TBV (Annual)1.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-15.45%
Cash Flow / Share (Quarterly)$-0.25
Price vs S&P 500 (YTD)-7.10%
Gross Margin (TTM)33.93%
Net Profit Margin (TTM)-37.19%
EPS (TTM)$-0.30
10-Day Avg Trading Volume2.07M
EPS Excl Extra (TTM)$-0.30
Revenue Growth (5Y)-15.82%
EPS (Annual)$-0.30
ROI (Annual)-13.96%
Gross Margin (Annual)33.93%
Net Profit Margin (5Y Avg)-20.18%
Cash / Share (Quarterly)$0.49
Revenue Growth QoQ (YoY)-19.14%
ROA (Last FY)-11.68%
Revenue Growth TTM (YoY)-14.90%
EBITD / Share (TTM)$-0.17
ROE (5Y Avg)-11.62%
Operating Margin (TTM)-34.46%
Cash Flow / Share (Annual)$-0.25
P/B Ratio0.73x
P/B Ratio (Quarterly)0.76x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.49x
Net Interest Coverage (TTM)-5.85x
ROA (TTM)-11.24%
EPS Growth QoQ (YoY)-22.63%
EV / EBITDA (TTM)7.32x
EPS Incl Extra (Annual)$-0.30
Current Ratio (Annual)3.97x
Quick Ratio (Quarterly)3.43x
3-Month Avg Trading Volume2.95M
52-Week Price Return-14.08%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.73
P/S Ratio (Annual)1.53x
Asset Turnover (Annual)0.31x
52-Week High$1.60
Operating Margin (5Y Avg)-19.09%
EPS Excl Extra (Annual)$-0.30
CapEx CAGR (5Y)-18.29%
Tangible BV CAGR (5Y)-1.70%
26-Week Price Return-19.21%
Quick Ratio (Annual)3.43x
13-Week Price Return-4.69%
Total Debt / Equity (Annual)0.28x
Current Ratio (Quarterly)3.97x
Enterprise Value$906.038
Revenue / Share Growth (5Y)-18.45%
Asset Turnover (TTM)0.30x
Book Value / Share Growth (5Y)-7.71%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)6.54x
Pretax Margin (Annual)-39.77%
Cash / Share (Annual)$0.48
3-Month Return Std Dev35.40%
Gross Margin (5Y Avg)32.58%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)11.35%
ROE (Last FY)-17.80%
Net Interest Coverage (Annual)-6.22x
EPS Basic Excl Extra (Annual)$-0.30
P/FCF (TTM)32.04x
Receivables Turnover (TTM)5.83x
Total Debt / Equity (Quarterly)0.28x
EPS Incl Extra (TTM)$-0.30
Receivables Turnover (Annual)5.83x
ROI (TTM)-13.53%
P/S Ratio (TTM)1.53x
Pretax Margin (5Y Avg)-20.47%
Revenue / Share (Annual)$0.81
Tangible BV / Share (Annual)$0.73
Price vs S&P 500 (52W)-48.72%
Year-to-Date Return-3.17%
5-Day Price Return4.27%
EPS Normalized (Annual)$-0.30
ROA (5Y Avg)-7.98%
Net Profit Margin (Annual)-37.19%
Month-to-Date Return7.02%
Cash Flow / Share (TTM)$-0.14
EBITD / Share (Annual)$-0.17
Operating Margin (Annual)-34.46%
LT Debt / Equity (Annual)0.26x
ROI (5Y Avg)-9.58%
LT Debt / Equity (Quarterly)0.26x
EPS Basic Excl Extra (TTM)$-0.30
P/TBV (Quarterly)1.74x
P/B Ratio (Annual)0.76x
Inventory Turnover (TTM)6.54x
Pretax Margin (TTM)-39.77%
Book Value / Share (Annual)$1.67
Price vs S&P 500 (13W)-7.07%
Beta1.49x
P/FCF (Annual)151.81x
Revenue / Share (TTM)$0.79
ROE (TTM)-17.42%
52-Week Low$1.09
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OPKOpko Health Inc. | 1.53x | -14.90% | 33.93% | — | $1.22 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
OPKO Health is a diversified biotechnology company with pharmaceutical and diagnostics segments operating globally. Its diagnostics division, which generates the majority of revenue, operates clinical and genomics laboratories through BioReference and point-of-care services. The pharmaceutical segment focuses on research, development, and commercial operations across multiple countries.